Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies
Article excerpt
Highlighted: the sentence this signal was extracted from
GALWAY, Ireland, Nov. 16, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT ), the global leader in healthcare technology, today announced its intent to acquire Contego Medical, a privately held medical device company focused on innovative solutions for carotid artery disease and peripheral thrombectomy. The acquisition will build on the company's successful, exclusive U.S. distribution agreement with Contego, first announced in January 2025, and advances the Medtronic strategy of pursuing targeted investments that strengthen the company's core franchises. The deal specifically expands the Medtronic portfolio of differentiated carotid technologies, broadening patient access to innovative therapies for carotid artery and peripheral vascular disease. "With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease," said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health, which is part of the company's Cardiovascular portfolio. "By pairing Medtronic's deep clinical expertise in peripheral and neurovascular technologies with Contego's next-generation treatments backed by strong and consistent clinical data, â we intend to become an undisputed leader in carotid revascularization." Carotid artery disease occurs when the carotid arteries, the major blood vessels supplying the...
Keep reading with a free account
The rest of this article, and every signal for Medtronic, is in your free account.
